Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

Publikation: Bidrag til tidsskriftReviewForskningpeer review


  1. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The CLL comorbidity index in a population-based cohort: a tool for clinical care and research

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Artificial intelligence models in chronic lymphocytic leukemia - recommendations toward state-of-the-art

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Chronic lymphocytic leukaemia clones are detectable decades before diagnosis

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  • William G Wierda
  • Andrew Rawstron
  • Florence Cymbalista
  • Xavier Badoux
  • Davide Rossi
  • Jennifer R Brown
  • Alexander Egle
  • Virginia Abello
  • Eduardo Cervera Ceballos
  • Yair Herishanu
  • Stephen P Mulligan
  • Carsten U Niemann
  • Colin P Diong
  • Teoman Soysal
  • Ritsuro Suzuki
  • Hoa T T Tran
  • Shang-Ju Wu
  • Carolyn Owen
  • Stephan Stilgenbauer
  • Paolo Ghia
  • Peter Hillmen
Vis graf over relationer

Assessment of measurable residual disease (often referred to as "minimal residual disease") has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and has been correlated with time-to-event outcomes in chronic lymphocytic leukemia. Undetectable-measurable residual disease status at the end of treatment demonstrated independent prognostic significance in chronic lymphocytic leukemia, correlating with favorable progression-free and overall survival with chemoimmunotherapy. Given its utility in evaluating depth of response, determining measurable residual disease status is now a focus of outcomes in chronic lymphocytic leukemia clinical trials. Increased adoption of measurable residual disease assessment calls for standards for nomenclature and outcomes data reporting. In addition, many basic questions have not been systematically addressed. Here, we present the work of an international, multidisciplinary, 174-member panel convened to identify critical questions on key issues pertaining to measurable residual disease in chronic lymphocytic leukemia, review evaluable data, develop unified answers in conjunction with local expert input, and provide recommendations for future studies. Recommendations are presented regarding methodology for measurable residual disease determination, assay requirements and in which tissue to assess measurable residual disease, timing and frequency of assessment, use of measurable residual disease in clinical practice versus clinical trials, and the future usefulness of measurable residual disease assessment. Nomenclature is also proposed. Adoption of these recommendations will work toward standardizing data acquisition and interpretation in future studies with new treatments with the ultimate objective of improving outcomes and curing chronic lymphocytic leukemia.

Udgave nummer11
Sider (fra-til)3059-3072
Antal sider14
StatusUdgivet - nov. 2021

Bibliografisk note

© 2021. The Author(s).

ID: 73916837